Biogen Unveils Groundbreaking Alzheimer's Disease Research at AAIC 2026

Biogen Inc. is set to present its latest advancements in Alzheimer's disease research at the Alzheimer's Association International Conference (AAIC) 2026, taking place in London, UK, from July 12-15. The company will unveil new data across its Alzheimer's disease portfolio, including Phase 2 CELIA data for diranersen, an investigational tau-targeting antisense oligonucleotide (ASO), and emerging data on lecanemab, a treatment for early Alzheimer's disease.

The upcoming presentations will highlight Biogen's commitment to innovation in Alzheimer's care, spanning treatment delivery, real-world evidence, and approaches targeting core pathologies, including amyloid and tau. According to Priya Singhal, M.D., M.P.H., Executive Vice President and Head of Development at Biogen, the company remains dedicated to advancing research in Alzheimer's disease, with a focus on addressing abnormal tau, a key target in the disease.

Diranersen, Biogen's investigational ASO, has shown promising results in reducing tau production at its source. The Phase 2 CELIA study, which will be presented at AAIC, evaluated diranersen in patients with early Alzheimer's disease. The presentation will feature initial clinical, biomarker, and safety results from the study, providing further insight into the potential of tau reduction as a therapeutic approach.

In addition to diranersen, Biogen will also present new data on lecanemab, including emerging clinical evidence and practical use considerations for subcutaneous administration. The company will also share real-world evidence from the multicenter LEADER study, which examined lecanemab use and outcomes across diverse U.S. clinical settings. These findings will provide valuable insights into the treatment landscape for early Alzheimer's disease.

The AAIC 2026 presentations will underscore Biogen's leadership in Alzheimer's disease research and its continued commitment to innovation. With a strong focus on addressing core pathologies, including amyloid and tau, the company is poised to make significant strides in the development of effective treatments for this devastating disease. As the global Alzheimer's community gathers in London, Biogen's research will take center stage, offering new hope for patients and families affected by this condition.

Biogen's dedication to advancing Alzheimer's disease research is built on a foundation of scientific excellence and a passion for improving patient outcomes. As the company continues to push the boundaries of innovation, its work has the potential to transform the lives of millions of people worldwide. With the AAIC 2026 presentations, Biogen is poised to make a lasting impact on the field of Alzheimer's disease research, paving the way for a brighter future for patients, caregivers, and families affected by this devastating condition.

The upcoming presentations will provide a unique opportunity for the scientific community to engage with Biogen's latest research and gain a deeper understanding of the company's innovative approaches to Alzheimer's disease treatment. As the conference gets underway, the global Alzheimer's community will be watching with great interest, eager to learn more about the promising developments in this critical area of research.

With its strong portfolio of Alzheimer's disease treatments and a commitment to ongoing innovation, Biogen is well-positioned to drive progress in this field. The company's work has the potential to make a significant difference in the lives of patients and families affected by Alzheimer's disease, and its presentations at AAIC 2026 will be a major highlight of the conference.